Our study found that the TrxR1 targeting drug BS1801 can inhibit glioma cell proliferation, trigger ER stress, impair mitochondrial function, induce apoptosis and relief TMZ resistance through elevating ROS. The gene discussed is TXNRD1; the disease is central nervous system cancer.